Acteoside as a potential therapeutic option for primary hepatocellular carcinoma: a preclinical study

BACKGROUND: Hepatocellular carcinoma (HCC) is a common malignant tumor with characteristics of poor prognosis, high morbidity and mortality worldwide. In particular, only a few systemic treatment options are available for advanced HCC patients, and include sorafenib and the recently described atezol...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Di, Wang, Juan, Liu, Lu, Chen, Meiqi, Wang, Zhiyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7526186/
https://www.ncbi.nlm.nih.gov/pubmed/32993568
http://dx.doi.org/10.1186/s12885-020-07447-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7526186/
https://www.ncbi.nlm.nih.gov/pubmed/32993568
http://dx.doi.org/10.1186/s12885-020-07447-3

Ejemplares similares